Japan's Ministry of Health, Labor & Welfare approved Aegerion Pharmaceuticals Inc.'s (Nasdaq: AEGR) JUXTAPID to treat homozygous familial hypercholesterolemia. The stock price rose 57 cents to close at $3.06.
Japanese regulatory agency approves Aegerion Pharmaceuticals' JUXTAPID
September 29, 2016 at 17:43 PM EDT
